You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CABOZANTINIB S-MALATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cabozantinib s-malate and what is the scope of freedom to operate?

Cabozantinib s-malate is the generic ingredient in two branded drugs marketed by Exelixis and Exelixis Inc, and is included in two NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cabozantinib s-malate has two hundred and thirty-one patent family members in thirty-two countries.

One supplier is listed for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CABOZANTINIB S-MALATE
Generic Entry Dates for CABOZANTINIB S-MALATE*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for CABOZANTINIB S-MALATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CABOZANTINIB S-MALATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
Children's Oncology GroupPhase 2/Phase 3
National Cancer Institute (NCI)Phase 2/Phase 3

See all CABOZANTINIB S-MALATE clinical trials

Pharmacology for CABOZANTINIB S-MALATE
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for CABOZANTINIB S-MALATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CABOMETYX Tablets cabozantinib s-malate 20 mg, 40 mg and 60 mg 208692 1 2019-08-16

US Patents and Regulatory Information for CABOZANTINIB S-MALATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-001 Apr 25, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CABOZANTINIB S-MALATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 ⤷  Subscribe ⤷  Subscribe
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-001 Apr 25, 2016 ⤷  Subscribe ⤷  Subscribe
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CABOZANTINIB S-MALATE

Country Patent Number Title Estimated Expiration
South Korea 102030447 ⤷  Subscribe
China 110818633 一种苹果酸盐及其晶型 (MALATE SALT AND CRYSTAL FORM THEREOF) ⤷  Subscribe
Eurasian Patent Organization 033513 СПОСОБЫ ПОЛУЧЕНИЯ ХИНОЛИНОВЫХ СОЕДИНЕНИЙ И ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ, СОДЕРЖАЩИХ ТАКИЕ СОЕДИНЕНИЯ (PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CABOZANTINIB S-MALATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213661 583 Finland ⤷  Subscribe
2213661 C 2014 036 Romania ⤷  Subscribe PRODUCT NAME: CABOZANTINIB SI ORICE FORMA ECHIVALENTA TERAPEUTIC AACESTUIA, INCLUSIV SARURILE ACCEPT DATE OF NATIONAL AUTHORISATION: 20140321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/890/001, EU/1/13/890/002, EU/1/13/890/003; DATE OF FIRST AUTHORISATION IN EEA: 20140321 ABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/13/890/001, EU/1/13/890/002, EU/1/13/890/003;
2213661 C20140029 00117 Estonia ⤷  Subscribe PRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

CABOZANTINIB S-MALATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Cabozantinib S-Malate

Introduction

Cabozantinib s-malate, a kinase inhibitor, has been a significant player in the oncology market, particularly in the treatment of various types of cancer. This article delves into the market dynamics and financial trajectory of this drug, highlighting its approval, usage, cost-effectiveness, and future prospects.

Approval and Indications

Cabozantinib s-malate is approved for several indications, including differentiated thyroid cancer, hepatocellular carcinoma, medullary thyroid cancer, and renal cell carcinoma. These approvals have been granted by regulatory bodies such as the FDA and the European Medicines Agency (EMA)[2][5].

Mechanism of Action

Cabozantinib s-malate works by blocking proteins that signal cancer cells to divide and new blood vessels to grow, thereby inhibiting tumor growth and spread. This targeted therapy approach has made it a valuable treatment option in oncology[5].

Market Position

The drug is marketed under different brand names, including Cabometyx and Cometriq, depending on the indication. Its market position is strengthened by its unique mechanism of action and the unmet medical needs it addresses, particularly in patients who have progressed after prior therapies[2][5].

Cost and Cost-Effectiveness

The cost of cabozantinib s-malate is substantial, with a price of $301.2943 per tablet or $8,436 per 28-day cycle. Cost-utility analyses have shown varying results regarding its cost-effectiveness. For instance, a Canadian analysis indicated an incremental cost-effectiveness ratio (ICER) of $206,389 per quality-adjusted life year (QALY) gained compared to best supportive care (BSC) alone. However, this ICER can vary significantly based on the assumptions used in the analysis, such as the extrapolation models for overall survival (OS) and health state utilities[1].

Financial Implications

The financial viability of cabozantinib s-malate is influenced by several factors, including its comparative added clinical benefit, market sales, and the costs associated with its development and administration. The drug has shown high early market sales, particularly in the oncology cohort, where it has outperformed other therapeutic areas. For example, oncology drugs like cabozantinib s-malate have average cumulative sales of $1,041 million over nine quarters post-launch, significantly higher than other drug cohorts[3].

Clinical Trials and Development

Cabozantinib s-malate is continuously being studied in various clinical trials to expand its indications and improve treatment outcomes. Currently, it is in Phase II trials for neuroendocrine cancer, with a phase transition success rate (PTSR) benchmark of 34% for progressing into Phase III[4].

Market Rewards for Comparative Added Clinical Benefit

The market tends to reward drugs with higher comparative added clinical benefit scores, and cabozantinib s-malate is no exception. Its significant clinical benefits in treating advanced cancers have translated into strong market performance and financial returns[3].

Regulatory and Public Health Impact

The EMA granted an accelerated assessment for cabozantinib s-malate due to its major public health interest, highlighting its positive benefit-risk balance and the comprehensive data provided by the applicant. This accelerated approval process reflects the drug's potential to address unmet medical needs and its impact on medical practice[2].

Sensitivity and Scenario Analyses

Sensitivity and scenario analyses have been conducted to assess the robustness of the cost-effectiveness estimates. These analyses have shown that the ICER can vary widely based on different assumptions, such as the choice of OS extrapolation models and health state utility values. For instance, using a single exponential model to extrapolate OS data post-trial resulted in a significantly higher ICER of $281,727[1].

Future Prospects

Given its current market performance and ongoing clinical trials, cabozantinib s-malate is poised for continued growth. The drug's likelihood of approval for new indications, such as neuroendocrine cancer, will further expand its market reach. GlobalData's analysis suggests that the drug-specific phase transition and likelihood of approval scores are critical in predicting its future success[4].

Conclusion

Cabozantinib s-malate has established itself as a valuable treatment option in the oncology market, with significant clinical benefits and a strong financial trajectory. Its cost-effectiveness, while subject to various assumptions, underscores the need for careful economic evaluations. As the drug continues to be studied in new indications and its market position evolves, it is likely to remain a major player in the treatment of advanced cancers.

Key Takeaways

  • Approval and Indications: Cabozantinib s-malate is approved for several types of cancer, including differentiated thyroid cancer, hepatocellular carcinoma, medullary thyroid cancer, and renal cell carcinoma.
  • Cost and Cost-Effectiveness: The drug is expensive, with an ICER that can vary significantly based on the analysis assumptions.
  • Market Performance: It has strong early market sales, particularly in the oncology cohort.
  • Clinical Trials: Ongoing trials aim to expand its indications, including a Phase II trial for neuroendocrine cancer.
  • Regulatory Impact: Accelerated approval reflects its major public health interest and positive benefit-risk balance.
  • Future Prospects: Continued growth is expected, driven by new indications and strong market performance.

FAQs

Q: What is cabozantinib s-malate used for? A: Cabozantinib s-malate is used to treat various types of cancer, including differentiated thyroid cancer, hepatocellular carcinoma, medullary thyroid cancer, and renal cell carcinoma.

Q: How does cabozantinib s-malate work? A: It works by blocking proteins that signal cancer cells to divide and new blood vessels to grow, thereby inhibiting tumor growth and spread.

Q: What is the cost of cabozantinib s-malate? A: The cost is $301.2943 per tablet or $8,436 per 28-day cycle.

Q: Is cabozantinib s-malate cost-effective? A: The cost-effectiveness varies based on the analysis assumptions, with ICERs ranging from $206,389 to $281,727 per QALY gained.

Q: What are the future prospects for cabozantinib s-malate? A: The drug is expected to continue growing, driven by ongoing clinical trials and potential new indications, such as neuroendocrine cancer.

Sources

  1. NCBI: Pharmacoeconomic Review - Cabozantinib (Cabometyx)[1].
  2. EMA: CHMP assessment report - CABOMETYX[2].
  3. ASPE: Antimicrobial Drugs Market Returns Analysis[3].
  4. Pharmaceutical Technology: Cabozantinib s-malate by Ipsen for Neuroendocrine Cancer[4].
  5. NCI: Cabozantinib-S-Malate[5].

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.